These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28230018)

  • 1. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
    Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
    J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.
    Gruber-Rouh T; Naguib NN; Eichler K; Ackermann H; Zangos S; Trojan J; Beeres M; Harth M; Schulz B; Nour-Eldin A NE; Vogl TJ
    Int J Cancer; 2014 Mar; 134(5):1225-31. PubMed ID: 23960002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer.
    You YT; Changchien CR; Huang JS; Ng KK
    Int J Colorectal Dis; 2006 Jan; 21(1):33-7. PubMed ID: 15942741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases.
    Niitsu H; Hinoi T; Shimomura M; Egi H; Hattori M; Ishizaki Y; Adachi T; Saito Y; Miguchi M; Sawada H; Kochi M; Mukai S; Ohdan H
    World J Surg Oncol; 2015 Apr; 13():162. PubMed ID: 25908502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
    Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
    Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J
    Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
    Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
    Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
    Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT
    Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
    Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M;
    AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates.
    Vogl TJ; Kreutztr├Ąger M; Gruber-Rouh T; Eichler K; Nour-Eldin NE; Zangos S; Naguib NN
    Eur J Radiol; 2014 Oct; 83(10):1804-10. PubMed ID: 25082479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
    Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X
    Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
    M├╝ller H; Nakchbandi W; Chatzissavvidis I; Valek V
    Eur J Surg Oncol; 2001 Nov; 27(7):652-61. PubMed ID: 11669594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results.
    Vogl TJ; Gruber-Rouh T; Eichler K; Nour-Eldin NE; Trojan J; Zangos S; Naguib NN
    Eur J Radiol; 2013 Feb; 82(2):258-63. PubMed ID: 23127803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.